INTS earnings / call / takeaways
INTS Q3 FY26 earnings call: key takeaways
What INTS said on its earnings call of November 5, 2026: results against expectations, what changed since last quarter, guidance and the questions analysts pressed on.
By Lician·November 5, 2026·AI-generated from the call transcript and Lician data
- The company reported a net loss of $3.5 million for the third quarter of 2026, with no consensus estimate provided for EPS (2:09)
Results vs expectations
| Metric | Consensus | Reported | Result |
|---|---|---|---|
| EPS | -$0.94 | – | – |
What changed since last quarter
- The company raised $1.5 million in net proceeds from the issuance of common stock during the third quarter of 2026. (2:09)
- The Phase III Invincible III study resumed patient enrollment in a limited number of U.S. sites after pausing in March 2025 due to funding constraints. (0:00)
- The company expects its operating cash burn to average approximately $1 million per month in the final quarter of 2026. (2:09)
What analysts pressed on
- Whether the localized skin irritation issues in the Invincible IV study have been resolved. (19:21)
- How the switch to density-based CT imaging will affect the interpretation of results in the Invincible III study. (24:19)
- The potential impact of capital constraints on the speed of patient enrollment in the Invincible III study. (21:29)
In their words
Read the full transcript with the AI summary, or listen on the company's official webcast.
Every past call in full and transcript search come with Lician Pro.
Written by AI from the automatic transcript of the company's public webcast and Lician's earnings data. Each sentence cites the passage it comes from, and a sentence with a figure that is not in its sources was removed. Not investment advice.